Microbiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation

References

• Hollister EB, Gao C, Versalovic J. Compositional and functional features of the gastrointestinal microbiome and their effects on human health. Gastroenterology. 2014;146(6):1449–1458.
   PubMed Web of Science ®Google Scholar
• Marchesi J, Shanahan F. The normal intestinal microbiota. Curr Opin Infect Dis. 2007;20:508–513.
   PubMed Web of Science ®Google Scholar
• Tetro J. Human microbiome Handbook. Lancaster, PA: DEStech; 2016.
   Google Scholar
• Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria. Córdoba. Argentina: Food and Agriculture Organization of the United Nations and World Health Organization; 2001 Oct [cited 2019 Jun 4]. Available from: http://www.fao.org/3/a-a0512e.pdf.
   Google Scholar
• de Vrese M, Schrezenmeir J. Probiotics, prebiotics, and synbiotics. Adv Biochem Eng Biotechnol. 2008;111:1–66.
   PubMed Web of Science ®Google Scholar
• Derrien M, van Hylckama Vlieg JET. Fate, activity, and impact of ingested bacteria within the human gut microbiota. Trends Microbiol. 2015;23(6):354–366.
   PubMed Web of Science ®Google Scholar
• Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic treg cell homeostasis. Science. 2013;341(6145):569–573.
   PubMed Web of Science ®Google Scholar
• Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66(4):569–580.
   PubMed Web of Science ®Google Scholar
• Wilson BC, Vatanen T, Cutfield WS, et al. The super-donor phenomenon in fecal microbiota transplantation. Front Cell Infect Microbiol. 2019;9:2.
   PubMed Web of Science ®Google Scholar
• Rao K, Young VB. Fecal microbiota transplantation for the management of clostridium difficile infection. Infect Dis Clin North Am. 2015 Mar;29(1):109–122.
   PubMed Web of Science ®Google Scholar
• Benno Y, He F, Hosoda M. Effects of Lactobacillus GG yoghurt on human intestinal microecology in Japanese subjects. Nutr Today. 1996;31(suppl):9S–11S.
   Google Scholar
• Bartlett JG. Antibiotic-associated diarrhea. Clin Infect Dis. 1992 Oct;15(4):573–581.
   PubMed Web of Science ®Google Scholar
• Lagier J-C, Million M, Hugon P, et al. Human gut microbiota: repertoire and variations. Front Cell Infect Microbiol. 2012;2:136.
   PubMed Web of Science ®Google Scholar
• Ohland CL, Macnaughton WK. Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol. 2010;298(6):G807–G819.
   PubMed Web of Science ®Google Scholar
• Jafarnejad S, Shab-bidar S, Speakman JR, et al. Probiotics reduce the risk of antibiotic-associated diarrhea in adults (18 – 64 years) but not the elderly (> 65 Years): a meta-analysis. Nutr Clin Pract. 2016;31(4):502–513.
   PubMed Web of Science ®Google Scholar
• Mcdonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1–e48.
   PubMed Web of Science ®Google Scholar
• Antharam VC, Li EC, Ishmael A, et al. Intestinal dysbiosis and depletion of butyrogenic bacteria in clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol. 2013;51(9):2884–2892.
   PubMed Web of Science ®Google Scholar
• Cushing K, Alvarado DM, Ciorba MA. Butyrate and mucosal inflammation: new scientific evidence supports clinical observation. Clin Transl Gastroenterol. 2015;6(8):e108.
   PubMedGoogle Scholar
• Shen NT, Maw A, Tmanova LL, et al. Timely use of probiotics in hospitalized adults prevents Clostridium difficile infection: A systematic review with meta-regression analysis. Gastroenterology. 2017;152(8):1889–1900.e9.
   PubMed Web of Science ®Google Scholar
• Goldenberg J, Yap C, Lytvyn L, et al. Probiotics for the prevention of clostridium difficile- associated diarrhea in adults and children (Review). Cochrane database Syst Rev. 2017.
   PubMed Web of Science ®Google Scholar
• Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478–498.
   PubMed Web of Science ®Google Scholar
• Zmora N, Zilberman-Schapira G, Suez J, et al. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell. 2018;174(6):1388–1405.e21.
   PubMed Web of Science ®Google Scholar
• Suez J, Zmora N, Zilberman-Schapira G, et al. Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT. Cell. 2018;174(6):1406–1423.e16.
   PubMed Web of Science ®Google Scholar
• Barker AK, Duster M, Valentine S, et al. A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO). J Antimicrob Chemother. 2017;72(11):3177–3180.
   PubMed Web of Science ®Google Scholar
• Mcfarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994;271(24):1913–1918.
   PubMed Web of Science ®Google Scholar
• Juul F, Garborg K, Bretthauer M, et al. Fecal microbiota transplantation for primary Clostridium difficile infection. New Engl J Med. 2018;378(26):2535–2536.
   PubMed Web of Science ®Google Scholar
• Camacho-Ortiz A, Gutierrez-Delgado EM, Garcia-Mazcorro JF, et al. Randomized clinical trial to evaluate the effect of fecal microbiota transplant for initial Clostridium difficile infection in intestinal microbiome. PLoS One. 2017;12(12):e0189768.
   PubMed Web of Science ®Google Scholar
• Adams SD, Mercer DW. Fulminant Clostridium difficile colitis. Curr Opin Crit Care. 2007;13(4):450–455.
   PubMed Web of Science ®Google Scholar
• Sailhamer EA, Carson K, Chang Y, et al. Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality. Arch Surg. 2009;144(5):433–440.
   PubMedGoogle Scholar
• Fischer M, Kao D, Mehta SR, et al. Predictors of early failure after fecal microbiota transplantation for the therapy of Clostridium difficile infection: A multicenter study. Am J Gastroenterol. 2016;111(7):1024–1031.
   PubMed Web of Science ®Google Scholar
• Cammarota G, Masucci L, Dinoi G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2015;41:835–843.
   PubMed Web of Science ®Google Scholar
• Fischer M, Sipe BW, Rogers NA, et al. Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate. Aliment Pharmacol Ther. 2015;42:470–476.
   PubMed Web of Science ®Google Scholar
• Fischer M, Sipe B, Cheng Y, et al. Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: a promising treatment approach. Gut Microbes. 2017;8(3):289–302.
   PubMed Web of Science ®Google Scholar
• Ianiro G, Masucci L, Quaranta G, et al. Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection - single versus multiple infusions. Aliment Pharmacol Ther. 2018;48:152–159.
   PubMed Web of Science ®Google Scholar
• Debast SB, Bauer MP, Kuijper EJ. European society of clinical microbiology and infectious diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20(Suppl 2):1–26.
   PubMed Web of Science ®Google Scholar
• Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high‐dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2002;31(4):1012–1017.
   Web of Science ®Google Scholar
• van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368(5):407–415.
   PubMed Web of Science ®Google Scholar
• Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: a randomized trial. Ann Intern Med. 2018;165(9):609–616.
   Web of Science ®Google Scholar
• Kao D, Roach B, Silva M, et al. Effect of oral capsule vs colonoscopy-delivered fecal microbiota transplantation on recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2017;318(20):1985–1993.
   PubMed Web of Science ®Google Scholar
• Weingarden AR, Hamilton MJ, Sadowsky MJ, et al. Resolution of severe Clostridium difficile infection following sequential fecal microbiota transplantation. J Clin Gastroenterol. 2013;47(8):735–737.
   PubMed Web of Science ®Google Scholar
• Jiang ZD, Ajami NJ, Petrosino JF, et al. Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridum difficile infection – fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy. Aliment Pharmacol Ther. 2017;45:899–908.
   PubMed Web of Science ®Google Scholar
• Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA. 2019;315(2):142–149.
   Google Scholar
• Hvas CL, Jørgensen SMD, Erikstrup C, et al. Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection. Gastroenterology. 2019;156(5):1324–1332.e3.
   PubMed Web of Science ®Google Scholar
• Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies [Internet]. Vol. 78. Silver Spring (MD): Center for Biologics Evaluation and Research. 2016 Mar [cited 2019 Jun 4]. p. 42965–42966. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-regarding-investigational-new-drug-requirements-use-fecal-microbiota-0
   Google Scholar
• Binder HJ. Pathophysiology of acute diarrhea. Am J Med. 1990;88(Suppl6A):S2–4.
   Google Scholar
• Guarino A, Ashkenazi S, Gendrel D, et al. European society for pediatric gastroenterology, hepatology, and nutrition/European society for pediatric infectious diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. JPGN. 2014;59:132–152.
   Google Scholar
• Buydens P, Debeuckelaere S. Efficacy of SF 68 in the treatment of acute diarrhea. A placebo-controlled trial. Scand J Gastroenterol. 1996 Sep;31(9):887–891.
   PubMed Web of Science ®Google Scholar
• Wunderlich PF, Braun L, Fumagalli I, et al. Double-blind report on the efficacy of lactic acid-producing enterococcus sf68 in the prevention of antibiotic- associated diarrhoea and in the treatment of acute diarrhoea. J Int Med Res. 1989;17(4):333–338.
   PubMed Web of Science ®Google Scholar
• Mansour-ghanaei F, Dehbashi N, Yazdanparast K, et al. Efficacy of saccharomyces boulardii with antibiotics in acute amoebiasis. World J Gastroenterol. 2003;9(8):1832–1833.
   PubMed Web of Science ®Google Scholar
• Besirbellioglu BA, Ulcay A, Can M, et al. Saccharomyces boulardii and infection due to Giardia lamblia. Scand J Infect Dis. 2006;38(6–7):479–481.
   PubMed Web of Science ®Google Scholar
• Sheele J, Cartowski J, Dart A, et al. Saccharomyces boulardii and bismuth subsalicylate as low-cost interventions to reduce the duration and severity of cholera. Pathog Glob Health. 2015;109(6):275–282.
   PubMed Web of Science ®Google Scholar
• Mitra AK, Rabbani GH. A double-blind, controlled trial of bioflorin (Streptococcus faecium SF68) in adults with acute diarrhea due to Vibrio cholerae and enterotoxigenic Escherichia coli. Gastroenterology. 1990 Oct;99(4):1149–1152.
   PubMed Web of Science ®Google Scholar
• Riddle MS, Connor BA, Beeching NJ, et al. Guidelines for the prevention and treatment of travelers’ diarrhea: a graded expert panel report. J Travel Med Med. 2017;24(suppl_1):S57–74.
   PubMedGoogle Scholar
• Kollaritsch HH, Kremsner P, Wiedermann G, et al. Prevention of traveller’s diarrhea: comparison of different non-antibiotic preparations.Travel Med Int. 1989;1–9.
   Google Scholar
• Black FT, Andersen PL, Gaarslev K, et al. Prophylactic efficacy of Lactobacilli on traveler’s diarrhea. In: Steffen R, Lobel H, Haworth J, et al., editors. Travel medicine. Berlin, Heidelberg: Springer; 1989. p. 333–335.
   Google Scholar
• Katelaris PH, Salam I, Farthing MJG. Lactobacilli to prevent traveler’s diarrhea? N Engl J Med. 1995 Nov 16;333(20):1360–1361.
   PubMed Web of Science ®Google Scholar
• Lesbros-pantoflickova D, Corthe´sy-Theulaz I, Blum AL. Helicobacter pylori and probiotics. J Nutr. 2007;137:812S–818S.
   PubMed Web of Science ®Google Scholar
• Koretz RL. Probiotics in gastroenterology: how pro is the evidence in adults? Am J Gastroenterol. 2018;113(8):1125–1136.
   PubMed Web of Science ®Google Scholar
• Cindoruk M, Erkan G, Karakan T, et al. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti- Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter. 2007;12(4):309–316.
   PubMed Web of Science ®Google Scholar
• Manichanh C, Bonnaud E, Gloux K, et al. Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut. 2006;55:205–211.
   PubMed Web of Science ®Google Scholar
• Leone V, Chang EB, Devkota S. Diet, microbes, and host genetics: the perfect storm in inflammatory bowel diseases. J Gastroenterol. 2013;48(3):315–321.
   PubMed Web of Science ®Google Scholar
• Ni J, Wu GD, Albenberg L, et al. Gut microbiota and IBD: causation or correlation? Nat Rev Gastroenterol Hepatol. 2017;14(10):573–584.
   PubMed Web of Science ®Google Scholar
• Morgan XC, Tickle TL, Sokol H, et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012;13(9):R79.
   PubMed Web of Science ®Google Scholar
• Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63(8):1275–1283.
   PubMed Web of Science ®Google Scholar
• Png CW, Linden SK, Gilshenan KS, et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol. 2010 Nov;105(11):2420–2428.
   PubMed Web of Science ®Google Scholar
• Shen J, Zuo Z-X, Mao A-P. Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn’s disease, and pouchitis: meta-analysis of randomized controlled trials. Inflamm Bowel Dis. 2014;20(1):21–35.
   PubMed Web of Science ®Google Scholar
• Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7(11):1202–1209, 1209.e1.
   PubMed Web of Science ®Google Scholar
• Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL # 3 as adjunctive to a standard pharmaceutical treatment : a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2010;105(10):2218–2227.
   PubMed Web of Science ®Google Scholar
• Ng SC, Plamondon S, Kamm MA, et al. Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis. Inflamm Bowel Dis. 2010;16(8):1286–1298.
   PubMed Web of Science ®Google Scholar
• Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999;354(9179):635–639.
   PubMed Web of Science ®Google Scholar
• Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients. Gastroenterology. 2015;149(1):102–109.e6.
   PubMed Web of Science ®Google Scholar
• Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: A randomised placebo-controlled trial. Lancet. 2017;389(10075):1218–1228.
   PubMed Web of Science ®Google Scholar
• Costello SP, Hughes PA, Waters O, et al. Effect of fecal microbiota transplantation on 8-week remission in patients with ulcerative colitis: A randomized clinical trial. JAMA. 2019;321(2):156–164.
   PubMed Web of Science ®Google Scholar
• Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149(1):110–118.
   PubMed Web of Science ®Google Scholar
• Costello SP, Soo W, Bryant RV, et al. Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis. Aliment Pharmacol Ther. 2017;46(3):213–224.
   PubMed Web of Science ®Google Scholar
• Blesl A, Rainer F, Wurm P, et al. P594 Predictors of non-response to repeated faecal microbiota transplantation in patients with therapy refractory ulcerative colitis. Poster session presented at: clinical: therapy and observation. 14th Congress of the European Crohn’s and Colitis Organisation; 2019 Mar 6–9; Copenhagen, Denmark.
   Google Scholar
• Fuentes S, Rossen NG, van der Spek MJ, et al. Microbial shifts and signatures of long-term remission in ulcerative colitis after faecal microbiota transplantation. ISME J. 2017;11(8):1877–1889.
   PubMed Web of Science ®Google Scholar
• Cui HH, Chen CL, Wang JD, et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol. 2004;10(10):1521–1525.
   PubMed Web of Science ®Google Scholar
• Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997;11:853–858.
   PubMed Web of Science ®Google Scholar
• Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617–1623.
   PubMed Web of Science ®Google Scholar
• Zocco MA, Dal Verme LZ, Cremonini F, et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 2006;23(11):1567–1574.
   PubMed Web of Science ®Google Scholar
• Wildt S, Nordgaard I, Hansen U, et al. A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis. 2011;5(2):115–121.
   PubMed Web of Science ®Google Scholar
• Yoshimatsu Y, Yamada A, Furukawa R, et al. Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis. World J Gastroenterol. 2015;21(19):5985–5994.
   PubMed Web of Science ®Google Scholar
• Sood A, Mahajan R, Singh A, et al. Role of fecal microbiota transplantation for maintenance of remission in patients with ulcerative colitis: a pilot study. J Crohns Colitis. 2019 March.
   PubMedGoogle Scholar
• Schultz M, Timmer A, Herfarth HH, et al. Lactobacillus GG in inducing and maintaining remission of Crohn’s disease. BMC Gastroenterol. 2004;4:5.
   PubMed Web of Science ®Google Scholar
• Malchow HA. Crohn’s disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn’s disease? J Clin Gastroenterol. 1997;25(4):653–658.
   PubMed Web of Science ®Google Scholar
• Steed H, Macfarlane GT, Blackett KL, et al. Clinical trial: the microbiological and immunological effects of synbiotic consumption - a randomized double-blind placebo-controlled study in active Crohn’s disease. Aliment Pharmacol Ther. 2010;32(7):872–883.
   PubMed Web of Science ®Google Scholar
• Cui B, Feng Q, Wang H, et al. Fecal microbiota transplantation through mid-gut for refractory Crohn’s disease: safety, feasibility, and efficacy trial results. J Gastroenterol Hepatol. 2015;30(1):51–58.
   PubMed Web of Science ®Google Scholar
• Vaughn BP, Vatanen T, Allegretti JR, et al. Increased intestinal microbial diversity following fecal microbiota transplant for active crohn’s disease. Inflamm Bowel Dis. 2016;22(9):2182–2190.
   PubMed Web of Science ®Google Scholar
• Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci. 2000 Jul;45(7):1462–1464.
   PubMed Web of Science ®Google Scholar
• Bourreille A, Cadiot G, Le Dreau G, et al. Saccharomyces boulardii does not prevent relapse of Crohn’s disease. Clin Gastroenterol Hepatol. 2013;11(8):982–987.
   PubMed Web of Science ®Google Scholar
• Willert RP, Peddi KK, Ombiga J, et al. T1235 Randomised, double-blinded, placebo-controlled study of VSL#3 versus placebo in the maintenance of remission in Crohns disease. Gastroenterology. 2010;138(5):S517–S518.
   Web of Science ®Google Scholar
• Zocco MA, Verme LZD, Armuzzi A, et al. Comparison of Lactobacillus GG and mesalazine in maintaining remission of ulcerative colitis and Crohn’s disease. Gastroenterology. 2003 Apr 1;124(4):A201. [Internet].
   Web of Science ®Google Scholar
• Marteau P, Lemann M, Seksik P, et al. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled GETAID trial. Gut. 2006;55:842–847.
   PubMed Web of Science ®Google Scholar
• Van Gossum A, Dewit O, Louis E, et al. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after lleo-caecal resection. Inflamm Bowel Dis. 2007;13(2):135–142.
   PubMed Web of Science ®Google Scholar
• Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG. Gut. 2002;51:405–409.
   PubMed Web of Science ®Google Scholar
• Fedorak RN, Feagan BG, Hotte N, et al. The Probiotic VSL # 3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13(5):928–35.e2.
   PubMed Web of Science ®Google Scholar
• Rodemann JF, Dubberke ER, Reske KA, et al. Incidence of clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5(3):339–344.
   PubMed Web of Science ®Google Scholar
• Khoruts A, Rank KM, Newman KM, et al. Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent Clostridium difficile infection. Clin Gastroenterol Hepatol. 2016;14(10):1433–1438.
   PubMed Web of Science ®Google Scholar
• Chin SM, Sauk J, Mahabamunuge J, et al. Fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease: A single-center experience. Clin Gastroenterol Hepatol. 2017;15(4):597–599.
   PubMed Web of Science ®Google Scholar
• Newman KM, Rank KM, Vaughn BP, et al. Treatment of recurrent Clostridium difficile infection using fecal microbiota transplantation in patients with inflammatory bowel disease. Gut Microbes. 2017;8(3):303–309.
   PubMed Web of Science ®Google Scholar
• Fischer M, Kao D, Kelly C, et al. Fecal microbiota transplantation is safe and efficacious for recurrent or refractory Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2016;22(10):2402–2409.
   PubMed Web of Science ®Google Scholar
• Allegretti JR, Hurtado J, Carrellas M, et al. The Icon Study: inflammatory bowel disease and recurrent Clostridium difficile infection: outcomes after fecal microbiota transplantation. Gastroenterology. 2019;156(6):S2–S3.
   Web of Science ®Google Scholar
• Mclaughlin SD, Walker AW, Churcher C, et al. The bacteriology of pouchitis: A molecular phylogenetic analysis using 16S rRNA gene cloning and sequencing. Ann Surg. 2010;252(1):90–98.
   PubMed Web of Science ®Google Scholar
• Shen BO. Pouchitis : what every gastroenterologist needs to know. Clin Gastroenterol Hepatol. 2013;11(12):1538–1549.
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124(5):1202–1209.
   PubMed Web of Science ®Google Scholar
• Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL # 3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53(1):108–114.
   PubMed Web of Science ®Google Scholar
• Gosselink MP, Schouten WR, van Lieshout LMC, et al. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum. 2004;47(6):876–884.
   PubMed Web of Science ®Google Scholar
• Pronio A, Montesani C, Butteroni C, et al. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis. 2008;14(5):662–668.
   PubMed Web of Science ®Google Scholar
• Kiusma J, Mentula S, Jarvinen H, et al. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther. 2003;17:509–515.
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. Gastroenterology. 2000;119(2):305–309.
   PubMed Web of Science ®Google Scholar
• Singh S, Stroud AM, Holubar SD, et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2015; 23(11):CD001176.
   PubMed Web of Science ®Google Scholar
• Holubar SD, Cima RR, Sandborn WJ, et al. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2010; 16(6):CD001176.
   PubMed Web of Science ®Google Scholar
• Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohn’s Colitis. 2017;11(6):649–670.
   Google Scholar
• Landy J, Al-Hassi HO, Mann ER, et al. Tu1985 A prospective controlled pilot study of fecal microbiota transplantation for chronic refractory pouchitis. Gastroenterology. 2013;144(5):S–897.
   Web of Science ®Google Scholar
• Herfarth H, Barnes EL, Long MD, et al. P591 Low donor microbial engraftment after combined endoscopic and oral faecal microbiota transplant (FMT) in patients with antibiotic dependent pouchitis. Poster session presented at: clinical: therapy and observation. 14th Congress of the European Crohn’s and Colitis Organisation; 2019 Mar 6–9; Copenhagen, Denmark.
   Google Scholar
• Selvig D, Piceno Y, Terdiman J, et al. Fecal microbiota transplantation in pouchitis: clinical, endoscopic, histologic, and microbiota results from a pilot study. Dig Dis Sci. 2019 Jul 13. DOI:10.1007/s10620-019-05715-2.
   PubMedGoogle Scholar
• Stallmach A, Lange K, Buening J, et al. Fecal microbiota transfer in patients with chronic antibiotic- refractory pouchitis. Am J Gastroenterol. 2016;111(3):441–443.
   PubMed Web of Science ®Google Scholar
• van Hemert S, Skonieczna-Żydecka K, Loniewski I, et al. Microscopic colitis —microbiome, barrier function and associated diseases. Ann Transl Med. 2018;6(3):39.
   PubMed Web of Science ®Google Scholar
• Rohatgi S, Ahuja V, Makharia GK, et al. VSL # 3 induces and maintains short-term clinical response in patients with active microscopic colitis: a two-phase randomised clinical trial. BMJ Open Gastroenterol. 2015;2(1):e000018.
   PubMed Web of Science ®Google Scholar
• Taheri A, Sadighi A, Nikkhoo B, et al. Evaluation of Effects and complications of probiotics in microscopic colitis, a double blind placebo control clinical trial. Gastroenterology. 2011 May 1;140(5):S–852. [Internet].
   Web of Science ®Google Scholar
• Wildt S, Munck LK, Vinter-Jensen L, et al. Probiotic treatment of collagenous colitis: a randomized, double-blind, placebo-controlled trial with Lactobacillus acidophilus and Bifidobacterium animalis subsp. Lactis Inflammation Bowel Dis. 2006 May;12(5):395–401.
   PubMed Web of Science ®Google Scholar
• Günaltay S, Rademacher L, Hörnquist EH, et al. Clinical and immunologic effects of faecal microbiota transplantation in a patient with collagenous colitis. World J Gastroenterol. 2017;23(7):1319–1324.
   PubMed Web of Science ®Google Scholar
• Schmulson MJ, Drossman DA, Words K. What is new in Rome IV. J Neurogastroenterol Motil. 2017;23(2):151–163.
   PubMed Web of Science ®Google Scholar
• Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016 Oct;1(2):133–146.
   PubMed Web of Science ®Google Scholar
• Rajilić-Stojanović M, Biagi E, Heilig HG, et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011;141(5):1792–1801.
   PubMed Web of Science ®Google Scholar
• Jeffery IB, O’Toole PW, Öhman L, et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut. 2012;61(7):997–1006.
   PubMed Web of Science ®Google Scholar
• Ford AC, Quigley EMM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systematic review and meta-analysis. Am J Gastroenterol. 2014;109(10):1547–1561.
   PubMed Web of Science ®Google Scholar
• Distrutti E, Monaldi L, Ricci P, et al. 2016 Irritable bowel syndrome: global view gut microbiota role in irritable bowel syndrome: new therapeutic strategies. World J Gastroenterol. 2016;22(7):2219–2241.
   PubMed Web of Science ®Google Scholar
• Mazurak N, Broelz E, Storr M, et al. Probiotic therapy of the Irritable Bowel Syndrome: why is the evidence still poor and what can be done about it? J Neurogastroenterol Motil. 2015;21(4):471–485.
   PubMed Web of Science ®Google Scholar
• Johnsen PH, Hilpüsch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: A double-blind, randomised, placebo-controlled, parallel-group, single-centre trial. Lancet Gastroenterol Hepatol. 2018;3(1):17–24.
   PubMed Web of Science ®Google Scholar
• Holvoet T, Joossens M, Jerina B, et al. 617 - Fecal microbiota transplantation in irritable bowel syndrome with predominant abdominal bloating: results from a double blind, placebo-controlled clinical trial. Gastroenterology. 2018 May 1;154(6):S–130. [Internet].
   Web of Science ®Google Scholar
• Aroniadis OC, Brandt LJ, Oneto C, et al. 742 - A double-blind, randomized, placebo-controlled trial of fecal microbiota transplantation capsules (FMTC) for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). Gastroenterology. 2018 May 1;154(6):S-154-S-155..
   Google Scholar
• Halkjaer SI, Christensen AH, Lo BZS, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018;67(12):2107–2115.
   PubMed Web of Science ®Google Scholar
• Scarpignato C, Barbara G, Lanas A, et al. Management of colonic diverticular disease in the third millennium: highlights from a symposium held during the United European gastroenterology week 2017. Therap Adv Gastroenterol. 2018;11:1756284818771305.
   Web of Science ®Google Scholar
• Barbara G, Scaioli E, Barbaro MR, et al. Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease. Gut. 2017;66:1252–1261.
   PubMed Web of Science ®Google Scholar
• Kvasnovsky CL, Leong LEX, Choo JM, et al. Clinical and symptom scores are significantly correlated with fecal microbiota features in patients with symptomatic uncomplicated diverticular disease: a pilot study. Eur J Gastroenterol Hepatol. 2018;30:1.
   PubMed Web of Science ®Google Scholar
• Lamiki P, Tsuchiya J, Pathak S, et al. Probiotics in diverticular disease of the colon: an open label study. J Gastrointestin Liver Dis. 2010;19(1):31–36.
   PubMed Web of Science ®Google Scholar
• Lahner E, Esposito G, Zullo A, et al. High-fibre diet and Lactobacillus paracasei B21060 in symptomatic uncomplicated diverticular disease. World J Gastroenterol. 2012;18(41):5918–5924.
   PubMed Web of Science ®Google Scholar
• Annibale B, Maconi G, Lahner E, et al. Efficacy of Lactobacillus paracasei sub. paracasei F19 on abdominal symptoms in patients with symptomatic uncomplicated diverticular disease: a pilot study. Minerva Gastroenterol Dietol. 2011;57(1):13–22.
   PubMedGoogle Scholar
• Kvasnovsky CL, Bjarnason I, Donaldson AN, et al. A randomized double-blind placebo-controlled trial of a multi-strain probiotic in treatment of symptomatic uncomplicated diverticular disease. Inflammopharmacology. 2017 May.
   PubMed Web of Science ®Google Scholar
• Ojetti V, Petruzziello C, Cardone S, et al. The use of probiotics in different phases of diverticular disease. Rev Recent Clin Trials. 2018;13(2):89–96.
   PubMed Web of Science ®Google Scholar
• Tursi A, Brandimarte G, Elisei W, et al. Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease – a double-blind, randomised, placebo-controlled study. Aliment Pharmacol Ther. 2013;38:741–751.
   PubMed Web of Science ®Google Scholar
• Kvasnovsky CL, Bjarnason I, Papagrigoriadis S. What colorectal surgeons should know about probiotics: a review. Colorectal Dis. 2015;17(10):840–848.
   PubMed Web of Science ®Google Scholar
• Robert A, Asano T. Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins. 1977 Aug;14(2):333–341.
   PubMedGoogle Scholar
• Hagiwara M, Kataoka K, Arimochi H, et al. Role of unbalanced growth of Gram-negative bacteria in ileal ulcer formation in rats treated with a nonsteroidal anti- inflammatory drug. J Med Investig. 2004;51(1–2):43–51.
   PubMedGoogle Scholar
• Reuter BK, Davies NM, Wallace JL. Nonsteroidal anti-inflammatory drug enteropathy in rats: role of permeability, bacteria, and enterohepatic circulation. Gastroenterology. 1997;112(1):109–117.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Masui A, Nakamura J, et al. Yogurt containing Lactobacillus gasseri mitigates aspirin-induced small bowel injuries: A prospective, randomized, double-blind, placebo-controlled trial. Digestion. 2017;95(1):49–54.
   PubMed Web of Science ®Google Scholar
• Endo H, Higurashi T, Hosono K, et al. Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users : a pilot randomized controlled study. J Gastroenterol. 2011;46(7):894–905.
   PubMed Web of Science ®Google Scholar
• Montalto M, Gallo A, Curigliano V, et al. Clinical trial: the effects of a probiotic mixture on non-steroidal anti-inflammatory drug enteropathy – A randomized, double-blind, cross-over, placebo-controlled study. Aliment Pharmacol Ther. 2010;32(2):209–214.
   PubMed Web of Science ®Google Scholar
• Boyle RJ, Robins-browne RM, Tang MLK. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006;83(6):1256–1264.
   PubMed Web of Science ®Google Scholar
• Lerner A, Shoenfeld Y, Matthias T. Probiotics: if it does not help it does not do any harm. really? Microorganisms. 2019;7:4.
   Web of Science ®Google Scholar
• Wang S, Xu M, Wang W, et al. Systematic review: adverse events of fecal microbiota transplantation. PLoS One. 2016;11(8):e0161174.
   PubMed Web of Science ®Google Scholar
• Panchal P, Budree S, Scheeler A, et al. Scaling Safe access to fecal microbiota transplantation: past, present, and future. Curr Gastroenterol Rep. 2018;20(4):14.
   PubMedGoogle Scholar
• Important safety alert regarding use of fecal microbiota for transplantation and risk of serious adverse reactions due to transmission of multi-drug resistant organisms [Internet]. Silver Spring (MD): US Food amd Drug Administration; [ updated 2019 Jun 13; cited 2019 Aug 27]. Available from: https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-safety-alert-regarding-use-fecal-microbiota-transplantation-and-risk-serious-adverse
   Google Scholar
• Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107(7):1079–1087.
   PubMed Web of Science ®Google Scholar
• Krajicek E, Fischer M, Allegretti JR, et al. Nuts and bolts of fecal microbiota transplantation. Clin Gastroenterol Hepatol. 2019;17(2):345–352.
   PubMed Web of Science ®Google Scholar